References
- DEY S, LEE KI, SUBHAN S, ASH JY, WASSERMAN A, FRISHMAN WH, et al. Hydroxychloroquine and Cardiotoxicity. Cardiol Rev. 2023 Mar 15. doi: 10.1097/CRD.0000000000000547. Epub ahead of print.
- GAGNON LR, SADASIVAN C, YOGASUNDARAM H, OUDIT GY. Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic. Curr Heart Fail Rep. 2022 Dec;19(6):458-466.
- YOGASUNDARAM H, PUTKO BN, TIEN J, PATERSON DI, CUJEC B, RINGROSE J, et al. Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. Can J Cardiol. 2014 Dec;30(12):1706-15.
- SCHREZENMEIER E, DÖRNER T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166.
- SIDDIQUI AK, HUBERFELD SI, WEIDENHEIM KM, EINBERG KR, EFFEREN LS. Hydroxychloroquine-induced toxic myopathy causing respiratory failure. Chest. 2007 Feb;131(2):588-90.
- SRINIVASA A, TOSOUNIDOU S, GORDON C. Increased Incidence of Gastrointestinal Side Effects in Patients Taking Hydroxychloroquine: A Brand-related Issue? J Rheumatol. 2017 Mar;44(3):398.
- NADEEM U, RAAFEY M, KIM G, TREGER J, PYTEL P, N HUSAIN A, et al. Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review. Am J Clin Pathol. 2021 May 18;155(6):793-801.
- TETT SE. Clinical pharmacokinetics of slow-acting antirheumatic drugs. Clin Pharmacokinet. 1993 Nov;25(5):392-407.
- MUBAGWA K. Cardiac effects and toxicity of chloroquine: a short update. Int J Antimicrob Agents. 2020 Aug;56(2):106057.
- BOYA P, GONZALEZ-POLO RA, PONCET D, ANDREAU K, VIEIRA HL, ROUMIER T, et al. Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene. 2003 Jun 19;22(25):3927-36.
- ABBASI S, TARTER L, FARZANEH-FAR R, FARZANEH-FAR A. Hydroxychloroquine: a treatable cause of cardiomyopathy. J Am Coll Cardiol. 2012 Aug 21;60(8):786.
- DELLA PORTA A, BORNSTEIN K, COYE A, MONTRIEF T, LONG B, PARRIS MA. Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians. Am J Emerg Med. 2020 Oct;38(10):2209-2217.
- JOYCE E, FABRE A, MAHON N. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. Eur Heart J Acute Cardiovasc Care. 2013 Mar;2(1):77-83.
- ABBASI S, TARTER L, FARZANEH-FAR R, FARZANEH-FAR A. Hydroxychloroquine: a treatable cause of cardiomyopathy. J Am Coll Cardiol. 2012 Aug 21;60(8):786.
- FRAM G, WANG DD, MALETTE K, VILLABLANCA P, KANG G, SO K, et al. Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19. Curr Cardiol Rev. 2021;17(3):319-327.
- COOPER LT, BAUGHMAN KL, FELDMAN AM, FRUSTACI A, JESSUP M, KUHL U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J. 2007 Dec;28(24):3076-93.
- YILMAZ A, KINDERMANN I, KINDERMANN M, MAHFOUD F, UKENA C, ATHANASIADIS A, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation. 2010 Aug 31;122(9):900-9.